Aridis Pharmaceuticals, Inc.
ARDS · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $1 | $1 |
| % Growth | – | -100% | -2.2% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $1 | $1 |
| % Margin | – | – | 100% | 100% |
| R&D Expenses | $26 | $38 | $17 | $24 |
| G&A Expenses | $7 | $7 | $6 | $6 |
| SG&A Expenses | $7 | $7 | $6 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$3 | -$2 | $0 | $0 |
| Operating Expenses | $30 | $44 | $23 | $30 |
| Operating Income | -$30 | -$44 | -$22 | -$29 |
| % Margin | – | – | -2,240.1% | -2,846.1% |
| Other Income/Exp. Net | -$0 | $0 | $0 | -$1 |
| Pre-Tax Income | -$30 | -$43 | -$22 | -$30 |
| Tax Expense | $0 | -$1 | $0 | $0 |
| Net Income | -$31 | -$42 | -$22 | -$30 |
| % Margin | – | – | -2,233.3% | -2,904.2% |
| EPS | -1.64 | -3.44 | -2.44 | -3.43 |
| % Growth | 52.3% | -41% | 28.9% | – |
| EPS Diluted | -1.64 | -3.44 | -2.44 | -3.43 |
| Weighted Avg Shares Out | 19 | 12 | 9 | 8 |
| Weighted Avg Shares Out Dil | 19 | 12 | 9 | 8 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | -$0 | $0 | $0 |
| Depreciation & Amortization | $0 | -$1 | $0 | $0 |
| EBITDA | -$30 | -$44 | -$22 | -$29 |
| % Margin | – | – | -2,206.4% | -2,813% |